Literature DB >> 23283817

Coexistence of gastrointestinal stromal tumors and gastric adenocarcinomas.

Yan Yan1, Ziyu Li, Yiqiang Liu, Lianhai Zhang, Jiyou Li, Jiafu Ji.   

Abstract

The purpose of this study is to detect the clinicopathology of gastrointestinal stromal tumors (GISTs) occurring synchronously with gastric adenocarcinomas and to unveil the potential underlying relationship between the synchronous GIST and gastric adenocarcinoma. This study included 15 patients with incidental GISTs found during operations for gastric adenocarcinoma and 30 patients who underwent gastrectomy for gastric cancer without discovering GIST between January 2005 and December 2010 at the Beijing Cancer Institute. We collected the clinicopathological data and analyzed the KIT/PDGFRA mutational status of GISTs, corresponding gastric adenocarcinoma specimens, and the normal tissue around the cancer lesions. Additionally, as a control group, the mutational status of the patients with gastric adenocarcinoma and no other tumors was assayed. Overall, 18 GISTs were found in 15 gastric adenocarcinoma patients. Multiple GIST lesions were found in three cases (20 %). The patients' age ranged from 46 to 85 years, with an average of 67.6 years. The average size of the GISTs was 0.85 cm. All mesenchymal lesions showed low proliferative activity, were of low or very low risk, and were identified as CD117-positive by immunostaining. In GIST lesions, mutations in KIT were detected in 7 out of 13 cases, and of these mutations, 6 were found in exon 11 (46.2 %), and 1 was found in exon 9 (7.7 %). A total of five deletions and one point mutation were in exon 11, and one insertion was in exon 9. Mutations were not detected in exon 17 or 13 of KIT. There was no remarkable mutation analyzed in the gastric adenocarcinoma lesions or normal tissues from either the test or control groups. Clinicopathological profiles and molecular analysis of KIT/PDGFRA showed no obvious relationship between gastric cancer and GISTs in tumor genesis, such as similar oncogene mutations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283817     DOI: 10.1007/s13277-012-0627-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

1.  Frequent c-Kit gene mutations not only in gastrointestinal stromal tumors but also in interstitial cells of Cajal in surrounding normal mucosa.

Authors:  Naotaka Ogasawara; Tetsuya Tsukamoto; Kenichi Inada; Tsutomu Mizoshita; Naoko Ban; Kenji Yamao; Takashi Joh; Makoto Itoh; Masae Tatematsu
Journal:  Cancer Lett       Date:  2005-12-18       Impact factor: 8.679

2.  [Dual tumours in the GI tract: synchronous and metachronous stromal (GIST) and epithelial/neuroendocrine neoplasms].

Authors:  Erika Kövér; Zsolt Faluhelyi; Barna Bogner; Katalin Kalmár; Gábor Horváth; Tamás Tornóczky
Journal:  Magy Onkol       Date:  2005-01-17

3.  Gastrointestinal stromal tumours in patients with other-type cancer: a mere coincidence or an etiological association? A study of 97 GIST cases.

Authors:  A Agaimy; P H Wuensch
Journal:  Z Gastroenterol       Date:  2005-09       Impact factor: 2.000

4.  Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS.

Authors:  Ana L Gomes; Ricardo H Bardales; Fernanda Milanezi; Rui M Reis; Fernando Schmitt
Journal:  Am J Clin Pathol       Date:  2007-01       Impact factor: 2.493

5.  Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.

Authors:  Warner K Huh; Michael W Sill; Kathleen M Darcy; Kevin M Elias; James S Hoffman; John F Boggess; Ronald D Alvarez; Harry J Long; David M O'Malley; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2010-02-26       Impact factor: 5.482

6.  Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.

Authors:  Bryan J Schneider; Gregory P Kalemkerian; Nithya Ramnath; Michael J Kraut; Antoinette J Wozniak; Francis P Worden; John C Ruckdeschel; Xiaohui Zhang; Wei Chen; Shirish M Gadgeel
Journal:  Clin Lung Cancer       Date:  2010-07-01       Impact factor: 4.785

Review 7.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

8.  Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions.

Authors:  Abbas Agaimy; Peter H Wünsch; Stephan Dirnhofer; Michel P Bihl; Luigi M Terracciano; Luigi Tornillo
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

Review 9.  Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.

Authors:  J Lasota; M Miettinen
Journal:  Histopathology       Date:  2008-02-28       Impact factor: 5.087

10.  Gastrointestinal stromal tumor.

Authors:  Xiaohui Zhao; Changjun Yue
Journal:  J Gastrointest Oncol       Date:  2012-09
View more
  8 in total

1.  Gastrointestinal stromal tumor with synchronous gallbladder adenocarcinoma.

Authors:  Julio A Diaz-Perez; Melina Mastrodimos; Abhinay Reddy
Journal:  J Gastrointest Cancer       Date:  2014-09

2.  Giant esophageal liposarcoma with squamous cell carcinoma resected via the cervical approach: a case report.

Authors:  Tomohiro Okura; Yasuhiro Shirakawa; Yuki Katsura; Takuya Yano; Michihiro Ishida; Daisuke Satoh; Yasuhiro Choda; Masanori Yoshimitsu; Nakano Kanyu; Hiroyoshi Matsukawa; Hitoshi Idani; Masazumi Okajima; Shigehiro Shiozaki
Journal:  Surg Case Rep       Date:  2022-06-20

3.  Additional malignancies in patients with gastrointestinal stromal tumors (GIST): incidence, pathology and prognosis according to a time of occurrence-based classification.

Authors:  J A Fernández; V Olivares; A J Gómez-Ruiz; B Ferri; M D Frutos; T Soria; G Torres; P Parrilla
Journal:  Clin Transl Oncol       Date:  2018-10-27       Impact factor: 3.405

4.  Synchronous occurrence of gastrointestinal stromal tumors and other digestive tract malignancies in the elderly.

Authors:  Chaoyong Shen; Haining Chen; Yuan Yin; Jiaju Chen; Luyin Han; Bo Zhang; Zhixin Chen; Jiaping Chen
Journal:  Oncotarget       Date:  2015-04-10

5.  Clinicopathological features and prognosis of coexistence of gastric gastrointestinal stromal tumor and gastric cancer.

Authors:  Zhen Liu; Shushang Liu; Gaozan Zheng; Jianjun Yang; Liu Hong; Li Sun; Daiming Fan; Hongwei Zhang; Fan Feng
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

6.  Multiscale network analysis reveals molecular mechanisms and key regulators of the tumor microenvironment in gastric cancer.

Authors:  Won-Min Song; Xiandong Lin; Xuehong Liao; Dan Hu; Jieqiong Lin; Umut Sarpel; Yunbin Ye; Yael Feferman; Daniel M Labow; Martin J Walsh; Xiongwei Zheng; Bin Zhang
Journal:  Int J Cancer       Date:  2019-10-11       Impact factor: 7.396

7.  Cross-testing of major molecular markers indicates distinct pathways of tumorigenesis in gastric adenocarcinomas and synchronous gastrointestinal stromal tumors.

Authors:  Éva Kocsmár; Ildikó Kocsmár; Luca Szalai; Gábor Lendvai; Attila Szijártó; Zsuzsa Schaff; András Kiss; Ilona Kovalszky; Gergő Papp; Gábor Lotz
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

8.  Prognostic analysis of gastric gastrointestinal stromal tumor with synchronous gastric cancer.

Authors:  Mi Lin; Jian-Xian Lin; Chang-Ming Huang; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu
Journal:  World J Surg Oncol       Date:  2014-01-31       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.